2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy
A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
- Writing Committee Members*;
- Bernard J. Gersh, MB, ChB, DPhil, FACC, FAHA, Co-Chair*†;
- Barry J. Maron, MD, FACC, Co-Chair*†;
- Robert O. Bonow, MD, MACC, FAHA‡;
- Joseph A. Dearani, MD, FACC§‖;
- Michael A. Fifer, MD, FACC, FAHA*†;
- Mark S. Link, MD, FACC, FHRS*¶;
- Srihari S. Naidu, MD, FACC, FSCAI*#;
- Rick A. Nishimura, MD, FACC, FAHA†;
- Steve R. Ommen, MD, FACC, FAHA†;
- Harry Rakowski, MD, FACC, FASE†**;
- Christine E. Seidman, MD, FAHA†;
- Jeffrey A. Towbin, MD, FACC, FAHA††;
- James E. Udelson, MD, FACC, FASNC‡‡§§;
- Clyde W. Yancy, MD, FACC, FAHA‖‖
+ Author Affiliations
- AHA Scientific Statements
- ablation
- cardiomyopathy, hypertrophic
- defibrillators, implantable
- hypertrophy
- myocardial disease
- surgical procedures, operative
Table of Contents
- Preamble . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .e785
- Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .e787
- 1.1. Methodology and Evidence Review . . . . . . . . . .e787
- 1.2. Organization of the Writing Committee . . . . . . .e787
- 1.3. Document Review and Approval. . . . . . . . . . . . .e787
- 1.4. Scope of the Guideline . . . . . . . . . . . . . . . . . . . .e788
- Prevalence/Nomenclature/Differential Diagnosis . . . .e788
- 2.1. Prevalence . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .e788
- 2.2. Nomenclature . . . . . . . . . . . . . . . . . . . . . . . . . . .e788
- 2.2.1. Historical Context. . . . . . . . . . . . . . . . . . .e788
- 2.2.2. Clinical Definition and Differential Diagnosis . . . . . . . . . . . . . . . . . . …
- Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .e787
No hay comentarios:
Publicar un comentario